Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2000
05/25/2000WO2000017233A3 Genes of the 1-desoxy-d-xylulose biosynthetic pathway
05/25/2000WO2000016762A3 Method for reducing nicotine dependency
05/25/2000WO2000016761A3 Serotonergic 5ht2 agonists for treating glaucoma
05/25/2000WO2000016759A3 Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty
05/25/2000WO2000016755A3 Antiviral combinations of lamivudine and adefovir
05/25/2000WO2000015788A3 Dna sequence encoding oncofetal ferritin protein
05/25/2000WO2000015210A3 Use of mycophenol acid and its derivatives for the treatment of virus diseases
05/25/2000WO2000015209A3 REGULATION OF HER2/neu ONCONGENE EXPRESSION BY SYNTHETIC POLYAMIDES
05/25/2000WO2000014228A8 Neutral amino acid transporter and gene thereof
05/25/2000WO2000012049A3 A method for the treatment of staphylococcal disease
05/25/2000WO2000009543A3 Hepatitis c inhibitor tri-peptides
05/25/2000WO2000004884A9 Pharmaceutical preparations for the topical treatment of mucocutaneous herpes infections and herpetic keratitis of the eye
05/25/2000WO1998049350A8 In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
05/25/2000DE19955793A1 CCR-3-Rezeptor-Antagonisten CCR-3 receptor antagonists
05/25/2000DE19937794A1 Composition useful for promoting wound healing comprises eugenol and polyphenols
05/25/2000DE19854147A1 Control of cocaine addiction comprises administration of N-substituted azabicycloalkane derivative
05/25/2000DE19854143A1 Antiprotozoal composition useful for treating e.g. piroplasmosis, malaria and sleeping sickness comprises pentamidine and an additional biocide
05/25/2000DE19854139A1 Antiprotozoal composition useful for e.g. treating malaria and sleeping sickness comprises diminazene diaceturate, glycerol and N-methylpyrrolidone
05/25/2000DE19853944A1 Use of diminazene diaceturate or pentamidine for treating malaria
05/25/2000DE19853937A1 Composition useful for treating e.g. malaria, babesiosis and trypanosomiasis comprises diminazene diaceturate and procaine
05/25/2000DE19853842A1 New water-soluble compound formed between allantoin and glyoxylic acid useful in cosmetic and/or pharmaceutical formulations
05/25/2000DE19853487A1 Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
05/25/2000DE19853425A1 Topical composition containing khellin or its derivatives, useful for phototherapy of psoriasis and eczema, has low mitogenic potential
05/25/2000DE19853278A1 New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis
05/25/2000CA2351695A1 Topical compositions including deodorant compositions
05/25/2000CA2351644A1 Pyrimidine derivatives and processes for the preparation thereof
05/25/2000CA2351585A1 Influencing of angigenesis using cd66a
05/25/2000CA2351576A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
05/25/2000CA2351522A1 Egf-like nucleic acids and polypeptides and uses thereof
05/25/2000CA2351516A1 Copolymer compositions for treating viral infections
05/25/2000CA2351314A1 Novel recombinant adenovirus
05/25/2000CA2351224A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain
05/25/2000CA2351187A1 Tetrahydroisoquinoline derivatives as lhrh antagonists
05/25/2000CA2351064A1 Drug delivery device, especially for the delivery of androgens
05/25/2000CA2351058A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
05/25/2000CA2350911A1 Hiv-specific t-cell induction
05/25/2000CA2350722A1 4-aroyl-piperidin-ccr-3 receptor antagonists iii
05/25/2000CA2350698A1 Human glycine transporter type 2
05/25/2000CA2350532A1 Excitatory amino acid receptor modulators
05/25/2000CA2350531A1 Method for treating pain
05/25/2000CA2350520A1 Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
05/25/2000CA2350501A1 Calcium fortified juice-based nutritional supplement
05/25/2000CA2350443A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors
05/25/2000CA2350420A1 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
05/25/2000CA2349919A1 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress
05/25/2000CA2349575A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
05/25/2000CA2349488A1 Pentaaza-cyclopenta¬a|naphthalene derivatives as ligands for gabaa alpha5 receptors
05/25/2000CA2348824A1 12 human secreted proteins
05/25/2000CA2348781A1 Compositions and methods for producing vascular occlusion
05/25/2000CA2348744A1 Method for producing an agent for treating non-cancerous pathologies of the organism
05/25/2000CA2348459A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
05/25/2000CA2317919A1 Cosmetic or dermatological use of 7-hydroxylated steroids alone and/or in combination with elastin derived peptides
05/24/2000EP1002805A1 Fixation inhibitors for helicobacter pylori
05/24/2000EP1002799A1 Optically pure androgen mediator
05/24/2000EP1002797A1 4,5-DIHYDRO- 1H]-BENZ g]INDAZOLE-3-CARBOXYLIC ACID DERIVATIVES
05/24/2000EP1002796A2 Novel quinoxalindione derivatives, their production and use in medicaments
05/24/2000EP1002795A1 HIV Replication inhibiting pyrimidines
05/24/2000EP1002794A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors
05/24/2000EP1002792A1 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
05/24/2000EP1002791A1 Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis
05/24/2000EP1002545A1 Suppressive agent against expression of cell adhesion molecules
05/24/2000EP1002544A1 Anti-edema agent
05/24/2000EP1002539A1 Immunomodulator comprising bacterial cells or cell wall decomposition products thereof
05/24/2000EP1002537A1 Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
05/24/2000EP1002536A2 2-Amino, 4-alkylamino pyrimidine 3-oxydes as soothing agents for the skin
05/24/2000EP1002535A1 New use of glutamate antagonists for the treatment of cancer
05/24/2000EP1002534A1 Bis-Staurosporine and K-252a derivatives
05/24/2000EP1002533A1 Use of chromanes and/or chromenes derivatives to prevent oxidative reactions induced by free radicals
05/24/2000EP1002532A1 Prevention of aging effects and treatment of muscle atrophy
05/24/2000EP1002531A1 A water-miscible composition of non-steroidal antiinflammatory drugs
05/24/2000EP1002530A2 Delivery systems for active ingredients comprising a salicylic acid derivative composition on a film structure and their use
05/24/2000EP1002525A2 N-acylate derivatives of pyrrolidone carboxylic acid as surfactant
05/24/2000EP1002104A1 Novel metalloprotease
05/24/2000EP1002082A2 Transcriptional silencer protein nrf
05/24/2000EP1002081A2 Delayed progression to aids by a missense allele of the ccr2 gene
05/24/2000EP1002068A1 Mutations in the myostatin gene cause double-muscling in mammals
05/24/2000EP1002065A1 Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations
05/24/2000EP1001993A1 Method for the continuous production of hydrolytically broken down and possibly substituted starch, use of hydrolytically broken down starch and device for producing same
05/24/2000EP1001984A1 NOVEL ESTROGEN RECEPTOR $g(b) AND ISOFORMS
05/24/2000EP1001983A1 NOVEL ESTROGEN $g(b) RECEPTOR AND ISOFORMS
05/24/2000EP1001975A1 Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
05/24/2000EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
05/24/2000EP1001970A1 Dipeptide derivatives as growth hormone secretagogues
05/24/2000EP1001964A1 Tango-78, tango-79, and tango-81 nucleic acid molecules and polypeptides
05/24/2000EP1001962A1 Production of avermectin compounds
05/24/2000EP1001961A2 Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same
05/24/2000EP1001957A1 Macrolides with antitumor activity
05/24/2000EP1001956A1 New 2,3-benzodiazepine derivatives
05/24/2000EP1001955A1 1,2,4-triazolo 4,3-b]pyrido 3,2-d]pyridazine derivatives and pharmaceutical compositions containing them
05/24/2000EP1001951A1 Thiazole derivatives, method for their production and use
05/24/2000EP1001946A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES
05/24/2000EP1001945A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES
05/24/2000EP1001944A1 Pyrazine derivatives, preparation and medicines containing them
05/24/2000EP1001943A1 Polyhydroxyalkylpyrazine derivatives, preparation and medicines containing them
05/24/2000EP1001942A1 Polyhydroxybutylpyrazines, their preparation and medicines containing them
05/24/2000EP1001941A1 Fused heterocyclic compounds and their use as kynurenine-3-hydroxylase inhibitors
05/24/2000EP1001940A1 Condensed pyrazole compounds
05/24/2000EP1001936A1 Bis -acridinecarboxamide having anti-tumor activity
05/24/2000EP1001935A1 Indole derivatives as mcp-1 receptor antagonists
05/24/2000EP1001934A1 Indole compounds as cox-2 inhibitors